following a full submission:
ferric maltol (Feraccru®) is not recommended for use within NHS Scotland.
Indication under review: in adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).
In a pooled analysis of two phase III studies in IBD patients with IDA who had failed previous treatment with oral ferrous products, there was a significantly greater increase in haemoglobin concentrations after 12 weeks of ferric maltol treatment compared with placebo.
The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC.
Download detailed advice219KB (PDF)
- Medicine name:
- ferric maltol (Feraccru)
- SMC ID:
- In adults for the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).
- Pharmaceutical company
- Shield Therapeutics
- BNF chapter
- Nutrition and blood
- Submission type
- Not recommended
- Date advice published
- 12 December 2016